Get the Stockscreener App
840.84
3.78%
30.60
After Hours:
844.72
3.88
+0.46%
Regeneron Pharmaceuticals Inc stock is traded at $840.84, with a volume of 744.71K.
It is up +3.78% in the last 24 hours and up +24.26% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$810.24
Open:
$817.17
24h Volume:
744.71K
Relative Volume:
0.77
Market Cap:
$86.57B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
20.49
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
+5.37%
1M Performance:
+24.26%
6M Performance:
+7.47%
1Y Performance:
+47.06%
1-Day Range:
$815.38
$844.92
1-Week Range:
$792.57
$844.92
52-Week Range:
$541.00
$844.92
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
US FDA approves Regeneron's rare bone disorder drug - reuters.com
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - Quiver Quantitative
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Oxbow Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meeder Asset Management Inc. Invests $4.46 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds near a 52-week high after a strong quarter. - Ad-hoc-news.de
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Promising Biotech Stocks To Watch TodayAugust 18th - MarketBeat
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - PR Newswire
Regeneron ends eye disease study due to antibody’s safety profile - biospace.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - TMX Newsfile
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile - biospace.com
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Resilient Regeneron stock trades close to 52-week high as dividend and earnings support valuation - AD HOC NEWS
UNIVEST FINANCIAL Corp Takes $8.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman Sobol Shapiro LLP - PR Newswire
Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Invests $160.53 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron halts early-stage uveitis trial after safety event - The Pharma Letter
4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI - MarketBeat
Deutsche Bank AG Makes New $323.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grandfield & Dodd LLC Purchases Shares of 36,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,778 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by B & T Capital Management DBA Alpha Capital Management - MarketBeat
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Samsung Biologics? No — Samchundang Pharm Reaches Landmark Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for Global Commercialization - finance.biggo.com
Regeneron Pharmaceuticals, Inc. Notice of September 14, - GlobeNewswire
Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron - GlobeNewswire
Biotech Stocks To ResearchAugust 17th - MarketBeat
Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run? - Kalkine Media
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
REGN Maintained by Leerink Partners -- Price Target Raised to $8 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners - MarketBeat
Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating - marketscreener.com
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
176.97%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):